Biotech Amgen posts Q2 net rise on higher sales of Enbrel, newer drugs, raises 2015 forecast

Higher sales of Amgen's blockbuster rheumatoid arthritis drug Enbrel and some newer drugs boosted second-quarter profit 7 percent.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.